# Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients

> **NCT00636740** · PHASE2 · COMPLETED · sponsor: **Merrion Pharmaceuticals, LLC** · enrollment: 30 (actual)

## Conditions studied

- Hormone-Refractory Prostate Cancer

## Interventions

- **DRUG:** Zoledronic Acid 20mg Tablets
- **DRUG:** Zoledronic Acid
- **DRUG:** Zoledronic Acid 20mg Tablets

## Key facts

- **NCT ID:** NCT00636740
- **Lead sponsor:** Merrion Pharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2009-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00636740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00636740, "Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00636740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*